Today 21 , 802818
Liu Y, Song Z, Liu Y, Ma X, Wang W, Ke Y, et al
Congress remained interested in the issue
Oral administration of PF-06882961 shows evidence of glucose-lowering in healthy human study participants PF-06882961 was selected as a candidate for clinical studies based on its in vitro and in vivo pharmacologic and disposition profile, including potent agonism of the GLP-1R, preclinical disposition attributes (e.g., low metabolic CL int in human hepatocytes), good safety margins versus the hERG channel (IC 50 = 4.3 M, Table S4) and broad panel screening (Table S8), and selectivity versus related class B GPCRs (Table S9)
Novo Nordisk stands behind the safety and efficacy of all of our GLP-1 medicines when they are used as indicated and when they are taken under the care of a licensed healthcare professional." "Well the drug was on the market for couple of years and all of a sudden lot of people had their gallbladder removed as a result of taking these drugs, (so) they updated the label," said Van Arsdale
Plasma concentrations decline with age - from approximately 200 ng/mL at age 20 to under 80 ng/mL by age 60